These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 14756541)

  • 41. Cancer/Testis OIP5 and TAF7L Genes are Up-Regulated in Breast Cancer.
    Mobasheri MB; Shirkoohi R; Modarressi MH
    Asian Pac J Cancer Prev; 2015; 16(11):4623-8. PubMed ID: 26107214
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Gene signatures for breast cancer, clinical utility and therapeutic applications].
    Vargas-Aguilar VM; Arroyo-Alvarez K
    Rev Med Inst Mex Seguro Soc; 2018; 56(2):180-185. PubMed ID: 29906029
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Protein interaction network (PIN)-based breast cancer subsystem identification and activation measurement for prognostic modeling.
    Lim S; Park Y; Hur B; Kim M; Han W; Kim S
    Methods; 2016 Nov; 110():81-89. PubMed ID: 27329435
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management.
    van Schooneveld E; Wildiers H; Vergote I; Vermeulen PB; Dirix LY; Van Laere SJ
    Breast Cancer Res; 2015 Feb; 17():21. PubMed ID: 25849621
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.
    Simonsson M; Veerla S; Markkula A; Rose C; Ingvar C; Jernström H
    BMC Cancer; 2016 Mar; 16():256. PubMed ID: 27029552
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Markers for the identification of late breast cancer recurrence.
    Sestak I; Cuzick J
    Breast Cancer Res; 2015 Jan; 17(1):10. PubMed ID: 25848913
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfite next-generation sequencing.
    Li Z; Guo X; Tang L; Peng L; Chen M; Luo X; Wang S; Xiao Z; Deng Z; Dai L; Xia K; Wang J
    Tumour Biol; 2016 Oct; 37(10):13111-13119. PubMed ID: 27449045
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biomarker research in breast cancer.
    Maxwell C
    Clin J Oncol Nurs; 2010 Dec; 14(6):771-83. PubMed ID: 21112854
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rational Approach to Finding Genes Encoding Molecular Biomarkers: Focus on Breast Cancer.
    Schneider N; Reed E; Kamel F; Ferrari E; Soloviev M
    Genes (Basel); 2022 Aug; 13(9):. PubMed ID: 36140706
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic and predictive biomarkers in breast cancer: Past, present and future.
    Nicolini A; Ferrari P; Duffy MJ
    Semin Cancer Biol; 2018 Oct; 52(Pt 1):56-73. PubMed ID: 28882552
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring.
    McGuire A; Brown JA; Kerin MJ
    Cancer Metastasis Rev; 2015 Mar; 34(1):145-55. PubMed ID: 25721950
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical application and utility of genomic assays in early-stage breast cancer: key lessons learned to date.
    Chia SKL
    Curr Oncol; 2018 Jun; 25(Suppl 1):S125-S130. PubMed ID: 29910655
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proteinases as Biomarkers in Breast Cancer Prognosis and Diagnosis.
    Suaifan GARY; Jaber D; Shehadeh MB; Zourob M
    Mini Rev Med Chem; 2017; 17(7):583-592. PubMed ID: 27281166
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of Novel Breast Cancer Subtype-Specific Biomarkers by Integrating Genomics Analysis of DNA Copy Number Aberrations and miRNA-mRNA Dual Expression Profiling.
    Li D; Xia H; Li ZY; Hua L; Li L
    Biomed Res Int; 2015; 2015():746970. PubMed ID: 25961039
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.
    Langerød A; Zhao H; Borgan Ø; Nesland JM; Bukholm IR; Ikdahl T; Kåresen R; Børresen-Dale AL; Jeffrey SS
    Breast Cancer Res; 2007; 9(3):R30. PubMed ID: 17504517
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aberrant miRNAs expressed in HER-2 negative breast cancers patient.
    Braicu C; Raduly L; Morar-Bolba G; Cojocneanu R; Jurj A; Pop LA; Pileczki V; Ciocan C; Moldovan A; Irimie A; Eniu A; Achimas-Cadariu P; Paradiso A; Berindan-Neagoe I
    J Exp Clin Cancer Res; 2018 Oct; 37(1):257. PubMed ID: 30342533
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.
    Krishnan P; Ghosh S; Wang B; Li D; Narasimhan A; Berendt R; Graham K; Mackey JR; Kovalchuk O; Damaraju S
    BMC Genomics; 2015 Sep; 16():735. PubMed ID: 26416693
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review.
    Chatterji S; Krzoska E; Thoroughgood CW; Saganty J; Liu P; Elsberger B; Abu-Eid R; Speirs V
    Lancet Oncol; 2023 Feb; 24(2):e74-e85. PubMed ID: 36725152
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy.
    Kyrochristos ID; Ziogas DE; Roukos DH
    Med Res Rev; 2019 May; 39(3):1205-1227. PubMed ID: 30417574
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular circuits of solid tumors: prognostic and predictive tools for bedside use.
    Ferté C; André F; Soria JC
    Nat Rev Clin Oncol; 2010 Jul; 7(7):367-80. PubMed ID: 20551944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.